- Home
- RYM vs INKT Comparison
RYM vs INKT Comparison
Compare RYM & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYM | INKT |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 45.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RYM | INKT |
|---|---|---|
| Price | $17.50 | $10.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 4.5K | ★ 175.6K |
| Earning Date | 03-03-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.00 | $6.66 |
| 52 Week High | $53.65 | $76.00 |
Technical Indicators
Market Signals| Indicator | RYM | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 51.54 |
| Support Level | $16.07 | $6.80 |
| Resistance Level | $18.87 | $12.64 |
| Average True Range (ATR) | 1.02 | 0.88 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 51.29 | 58.38 |
Price Performance
Historical ComparisonAbout RYM RYTHM Inc.
Rythm Inc is a USA Based company. The Company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.